Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

3 years ago

Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized,…

Jushi Holdings Inc. Debuts Line of Concentrate Products Using Hydrocarbon Extraction Diversifying its Offering of The Lab™ Vape and Concentrate Products

3 years ago

The Lab™ Live Resin’s Full-Spectrum, Aromatic Hydrocarbon Extracts Deliver Precise Effects, Flavorful Terpenes, High Purity and Freshness Jushi Holdings Debuts…

Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation

3 years ago

Leverages Mindset’s Platform Technology for Efficient Delivery of CNS TherapeuticsTORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:…

InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

3 years ago

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA…

VectivBio Announces Closing of $54 Million Aggregate Financing

3 years ago

BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel…

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

3 years ago

Neurona has initiated dosing of a first-ever regenerative human cell therapy candidate in a Phase 1/2 clinical trial for epilepsy…

Surface Oncology Appoints Carsten Brunn to Board of Directors

3 years ago

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target…

Tilray Medical Expands Portfolio of Medical Cannabis Products in the UK

3 years ago

LEAMINGTON, Ontario, June 29, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a…

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

3 years ago

Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4…

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

3 years ago

Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic…